Joshua Silverwood

Following a greenlight from the US FDA, Philips has enrolled the first patient in a trial of its newest intravascular lithotripsy catheter.

The artificial intelligence-powered device is used to guide patients through a hospital using voice recognition across any language.

The new biosensor device is designed to test for symmetric dimethylarginine, a chemical compound released in the early stages of chronic kidney disease (CKD).

The funding will be used to drive the growth of the company’s microfluidics manufacturing platform speeding up the development of devices.

The deal between the two is set to advance the company's blood test before rolling it out across more indications.

Early results from a trial of the company's Lunit SCOPE system found patients examined with the device saw a 35% lower risk of disease progression.

Following on from a previously granted FDA De Novo marketing authorisation, Momentis' second-generation Anovo robotic surgical platform had previously only seen use at a single site.

The deal between the two is set to advance Neurochase's Convection Enhanced Delivery designed to expedite drugs penetrating the brain.

Medical Device Network Shutterstock / FocalFinder The deal between the two will see Neurochase provided with electrospun components for the

Alongside expanded indications, the clearance allows for more people to MED-EL cochlear implant at earlier stages of hearing loss.